Grayson Sharpe leaned against his father's shoulder on Friday afternoon for good reason. The 16-year-old is fighting a hard battle against leukemia and is working to regain his strength. "I feel great," Sharpe said. Sharpe, who learned to play the ukulele during a half-year stay at a Cincinnati Children's Hospital, credits a drug he still knows little about, called vincristine, by helping him get out. "I heard the name (of the medicine). I saw the fluid pumping into me. And that's about it," Sharpe said. much of this chemo cocktail, if you will, "said his father, Aaron Sharp. Aaron Sharp recently learned that the pharmaceutical company Teva stopped making vincristine in the US. This left another drug maker, Pfizer, to take the weak one that led to "I know people (for whom) vincristine was really the only thing that worked for them," Sharpe said. In a statement, the director of oncology at Cincinnati Children's Hospital called the shortage "extremely disturbing." But Dr. John Perenthesis said, h is Children's Hospital "was strategic in the acquisition of medicines and we are confident that none of the child's results will be compromised." Perentesis said vincristine deficiency reflected "a recurring problem ̵
Grayson Sharpe leaned on his father's shoulder on Friday afternoon for a valid cause.  "I feel great," Sharpe said.
Sharpe, who learned to play the ukulele during a half-year stay at Cincinnati Children's Hospital, credits a medicine he still knows little about, called vincristine, by helping him get out.
"I heard the name (of the medicine). I saw the fluid pumping into me. And that's about it," Sharpe said.
"Vincristine was a big part of this chemo cocktail, if you will," says his father, Aaron Sharp.
Aaron Sharp recently taught the pharmaceutical company Teva to stop making vincristine in the US.
This left another drug maker, Pfizer, to deal with what led to production problems and shortages at the national level.
"I know people (for whom) vincristine was really the only thing I worked for," Sharpe said.
In a statement, the oncology director at Cincinnati Children Hospi Tal called the shortage "extremely disturbing." But Dr. John Prenthesis said Children's Hospital "was strategic in the acquisition of drugs and we are confident that none of the results of the child will be compromised."
Perthesis stated that vincristine deficiency reflected a "recurring problem – the economy of producing cheap, old, but highly effective cure rstva. In short, there is no incentive for pharmaceutical companies to make drugs like that. "
This is something that Grayson Sharpe and his father understand difficult.
"I think in America, the medical system is just so destroyed," says Grayson Sharp.
"I'm all for capitalism. It's great, but they make the business decision that they can't afford to continue to produce something that saves their lives. This is a concern," said Aaron Sharp.
WLWT News 5 investor Todd Dykes contacted a Teva spokesman on Thursday and received no response.
By Friday, the company made the following statement on its website:
"Theva accepts very much the importance of vincristine. We also understand the passion and pain that parents and patients can experience, but it is important to evaluate the facts.  "When Teva decided to stop the production of vincristine in the US, the company supplied only 3% of the market. The remaining 97% came from the manufacturer of the branded product. Based on this lack of demand for the Teva product at that time and to allow us to reconfigure our limited resources to e.g. other life-saving products needed on the market, Teva decided to suspend vincristine and alerted the FDA of its decision in March 2019. With data available, there is no shortage probability if the company leaves the market and the availability of a Teva product has not contributed to the shortage experienced today, we do not take the elimination of any of the products lightly and always carefully evaluate the need as thoroughly as possible (though in principle we are not aware of the challenges of supplying other products ers s can have). We are considering any and all opportunities to contribute to the solution now that we were aware that the branded product was in short supply. "
Meanwhile, Perenthesis said," Addressing the shortage must be a top priority among politicians. First, I believe we need an expert federal monitoring system to track low-risk medicines at risk, such as those with only one or two manufacturers. Second, incentives or other interventions are needed to ensure that companies continue to produce low-cost but critical drugs, such as vincristine. Continued treatment of children with cancer is at risk and we need action. "